I ran a test of the biotech & drug companies and found that the percentage of insiders vs the percentage of institutional owner does seem to make a difference. I still have about 500 stock to do, but I am making headway. Here is the beginning. I also placed at the end column how much growth the stock made if you bought and held the stock for six years- when applicable. Remember, some companies are only a few years old. Check out, if you can read this chart, how much it made in relation to the amount of insiders/institutional ownership. Don't draw any conclusions, but it is beginning to look kind of one-sided.
Can you imagine owning a company like AEGN for six years in your portfolio, knowing that the company is owned by 58% institutions and after six long years your $3000 initial investment is now worth $53? Are all the institutions dumb? No. Since perception is in fact a reflection of what you believe to be true, my discernment must be that there are other things considered when an institution buys a stock, and making money for its loyal mutual followers isn't it.
Stock Value Ins% inst% growth
AAA 7.5B 50% 1% $3,682.00
AAII 85.8M 29% 29% $171.00
ABAX 270.2M 4% 55% $12,788.00
ABC 6.7B 1% 93% $5,369.00
ABGX 960.4M 13% 85% $5,172.00
ABI 4.3B 1% 90% $2,251.00
ABMD 324.9M 22% 25% $7,032.00
ABRX 390.3M 4% 82% $25,589.00
ABT 67.6B 7% 62% $3,548.00
ACAM 1.1B 14% 3% $7,044.00
ACDO 1.3B 16% 95% $20,743.00
ACEL 145.6M 2% 10% $18,321.00
ACTG 91.6M 6% 16% $10,849.00
ADL 26.0M 15% 2% $600.00
ADLR 544.6M 6% 73% $1,489.00
ADRX 1.3B 2% 73% $5,159.00
AEGN 10.0M 23% 58% $53.00
AFFX 2.1B 0% 95% $10,961.00
AGEN 497.8M 51% 25% $473.00
AGIX 927.7M 3% 95% $3,807.00
AGN 10.2B 2% 88% $7,111.00
AI
Market Data 
Markets 
